|
![]() |
|||
|
||||
OverviewIn several liver diseases, the underlying cause cannot always be eliminated, i.e. the progression of liver disease cannot be prevented. This is particularly true for non-responders to the treatment of chronic hepatitis C (HCV). It is relevant for more than 40% of patients with HCV genotype 1 and up to 20% of patients with genotype 2 or 3. Several approaches are now underway to prevent or ameliorate mechanisms of disease progression. In Asia, and particularly in Japan, Glycyrrhizine-SNMC has been widely used for this purpose. At present, SNMC is under clinical evaluation in Europe. Full Product DetailsAuthor: N. Hiyashi , M.P. MannsPublisher: Springer Imprint: Springer Edition: 2004 ed. Volume: 138A Dimensions: Width: 15.50cm , Height: 0.90cm , Length: 23.50cm Weight: 0.830kg ISBN: 9780792387961ISBN 10: 0792387961 Pages: 130 Publication Date: 21 July 2004 Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: In Print ![]() This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us. Table of ContentsReviewsAuthor InformationTab Content 6Author Website:Countries AvailableAll regions |